Literature DB >> 8285631

Susceptibilities of Norwegian Candida albicans strains to fluconazole: emergence of resistance. The Norwegian Yeast Study Group.

P Sandven1, A Bjørneklett, A Maeland.   

Abstract

All Candida albicans isolates in Norwegian microbiological laboratories in 1991 judged clinically important (except vaginal isolates) were collected. The isolates were tested for susceptibility to fluconazole with an agar dilution test and a commercially available agar diffusion test. A total of 212 strains (95%) were susceptible to fluconazole, and MICs for most of the strains (92%) were < or = 1.56 micrograms/ml. The agar diffusion test using a 15-micrograms tablet and a 48-h incubation period separated resistant from susceptible strains with a wide margin. The only exception was a strain for which the MIC was 6.25 micrograms/ml. The difference in zone size between the resistant and the susceptible populations of strains was 11 mm. Accordingly, it appears that the agar diffusion test is an appropriate method for detecting fluconazole resistance. The 12 fluconazole-resistant isolates originated from eight AIDS patients with oral or esophageal Candida infections. Seven of the patients had been given fluconazole for 1 month or more, often as self medication. Four had infections that were clinically resistant to fluconazole; one additional patient responded only when the dose was increased. All isolates recovered from these patients were analyzed by multilocus enzyme electrophoresis. The 12 C. albicans isolates belonged to five electrophoretic types, but three of four patients attending one hospital had isolates belonging to one electrophoretic type. One possible explanation for this finding could be that a nosocomial spread of resistant strains has occurred.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8285631      PMCID: PMC192406          DOI: 10.1128/AAC.37.11.2443

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Candida albicans resistance in AIDS.

Authors:  V S Kitchen; M Savage; J R Harris
Journal:  J Infect       Date:  1991-03       Impact factor: 6.072

2.  Yeasts susceptibility testing.

Authors:  J Dupouy-Camet; A Paugam; C Tourte-Schaefer
Journal:  Lancet       Date:  1991-08-10       Impact factor: 79.321

3.  Fluconazole resistant candida in AIDS.

Authors:  D Smith; F Boag; J Midgley; B Gazzard
Journal:  J Infect       Date:  1991-11       Impact factor: 6.072

4.  Comparison of relative susceptibilities of Candida species to three antifungal agents as determined by unstandardized methods.

Authors:  J N Galgiani; J Reiser; C Brass; A Espinel-Ingroff; M A Gordon; T M Kerkering
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

Review 5.  Antifungal susceptibility tests.

Authors:  J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

6.  Effects of incubation temperature, inoculum size, and medium on agreement of macro- and microdilution broth susceptibility test results for yeasts.

Authors:  R A Cook; K A McIntyre; J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

7.  Laboratory identification and sensitivity testing of yeast isolates.

Authors:  P Sandven
Journal:  Acta Odontol Scand       Date:  1990-02       Impact factor: 2.331

8.  Effect of medium composition on results of macrobroth dilution antifungal susceptibility testing of yeasts.

Authors:  G V Doern; T A Tubert; K Chapin; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1986-10       Impact factor: 5.948

9.  Collaborative investigation of variables in susceptibility testing of yeasts.

Authors:  M A Pfaller; M G Rinaldi; J N Galgiani; M S Bartlett; B A Body; A Espinel-Ingroff; R A Fromtling; G S Hall; C E Hughes; F C Odds
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

Review 10.  Resistance of yeasts to azole-derivative antifungals.

Authors:  F C Odds
Journal:  J Antimicrob Chemother       Date:  1993-04       Impact factor: 5.790

View more
  32 in total

Review 1.  The ins and outs of DNA fingerprinting the infectious fungi.

Authors:  D R Soll
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

2.  Comparative study of agar diffusion test and the NCCLS macrobroth method for in vitro susceptibility testing of Candida spp.

Authors:  L M Soni; M N Burattini; A C Pignatari; O F Gompertz; A L Colombo
Journal:  Mycopathologia       Date:  1999       Impact factor: 2.574

Review 3.  Antifungal prophylaxis during neutropenia and immunodeficiency.

Authors:  O Lortholary; B Dupont
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

4.  Candidemia in Norway (1991 to 2003): results from a nationwide study.

Authors:  Per Sandven; Lars Bevanger; Asbjørn Digranes; Hanne H Haukland; Turid Mannsåker; Peter Gaustad
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

Review 5.  Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome.

Authors:  M A Ghannoum; J H Rex; J N Galgiani
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

Review 6.  Resistance of Candida species to fluconazole.

Authors:  J H Rex; M G Rinaldi; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

7.  Variation in fluconazole efficacy for Candida albicans strains sequentially isolated from oral cavities of patients with AIDS in an experimental murine candidiasis model.

Authors:  F Barchiesi; L K Najvar; M F Luther; G Scalise; M G Rinaldi; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

8.  In vitro activity of a new antifungal triazole, D0870, against Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus.

Authors:  F Barchiesi; A L Colombo; D A McGough; A W Fothergill; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

Review 9.  Fluconazole. An update of its antimicrobial activity, pharmacokinetic properties, and therapeutic use in vaginal candidiasis.

Authors:  C M Perry; R Whittington; D McTavish
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

10.  In vitro activity of amphotericin B, flucytosine and fluconazole against yeasts causing bloodstream infections.

Authors:  J Berenguer; V Fernández-Baca; R Sánchez; E Bouza
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-04       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.